简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:By Jonathan Stempel NEW YORK (Reuters) – The law firm that defended Martin Shkreli against antitrust charges said it has not been paid, and on Tuesday asked a U.S. judge for permission to withdraw from representing the former pharmaceutical executive best known for hiking the price
div classBodysc17zpet90 cdBBJodivpBy Jonathan Stempelp
pNEW YORK Reuters – The law firm that defended Martin Shkreli against antitrust charges said it has not been paid, and on Tuesday asked a U.S. judge for permission to withdraw from representing the former pharmaceutical executive best known for hiking the price of a lifesaving medication more than 40fold.pdivdivdiv classBodysc17zpet90 cdBBJodiv
pDuane Morris LLP said Shkrelis former company Phoenixus AG agreed to cover his legal fees but has refused to pay the 2.04 million owed through March 31, after exhausting the limits of an insurance policy covering the fees in October.p
pIn a filing in Manhattan federal court, Duane Morris also said Shkreli “has no assets” to pay its fees, and would not be harmed if it withdrew because the antitrust trial is over. The law firm said Shkreli did not oppose its withdrawal.p
pLawyers for Phoenixus did not immediately respond to requests for comment.p
pShkreli, 39, became known as “pharma bro” after raising the price of the antiparisitic drug Daraprim overnight to 750 per tablet from 17.50 in 2015, and appearing unrepentant when criticized.p
pIn January, U.S. District Judge Denise Cote in Manhattan banned Shkreli from the drug industry for life and ordered him to pay 64.6 million, finding he illegally sought to keep generic Daraprim rivals off the market.p
pThe case had been brought by the U.S. Federal Trade Commission and seven U.S. states.p
pShkreli is serving a sevenyear prison sentence after being convicted in 2017 of defrauding investors in two hedge funds he ran and scheming to defraud investors in another company.p
pHe is eligible for release on Nov. 7.p
pIn February, the Brooklyn judge who oversaw the criminal case and a related U.S. Securities and Exchange Commission civil case permanently banned Shkreli from serving as an officer or director of public companies.p
p
pp Reporting by Jonathan Stempel in New York Editing by Bernard Orrp
divdivdiv classBodysc17zpet90 cdBBJodivdivdiv
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.